CN108653716A - 一种茶叶精华解酒片及其制备方法 - Google Patents
一种茶叶精华解酒片及其制备方法 Download PDFInfo
- Publication number
- CN108653716A CN108653716A CN201810800886.6A CN201810800886A CN108653716A CN 108653716 A CN108653716 A CN 108653716A CN 201810800886 A CN201810800886 A CN 201810800886A CN 108653716 A CN108653716 A CN 108653716A
- Authority
- CN
- China
- Prior art keywords
- sobering
- tablet
- tealeaves
- essence
- tealeaves essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 235000005822 corn Nutrition 0.000 claims abstract description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 10
- 239000000845 maltitol Substances 0.000 claims abstract description 10
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims abstract description 10
- 235000010449 maltitol Nutrition 0.000 claims abstract description 10
- 229940035436 maltitol Drugs 0.000 claims abstract description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 7
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims abstract description 3
- 229940057948 magnesium stearate Drugs 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 239000004615 ingredient Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000005720 sucrose Substances 0.000 abstract description 2
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 20
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- 239000004201 L-cysteine Substances 0.000 description 11
- 235000013878 L-cysteine Nutrition 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 8
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 7
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 7
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000020339 pu-erh tea Nutrition 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 244000046146 Pueraria lobata Species 0.000 description 4
- 235000010575 Pueraria lobata Nutrition 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- -1 after people drinks Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种茶叶精华解酒片及其制备方法,该茶叶精华解酒片是提取发酵后茶叶精华、玉米肽、以及L‑半胱氨酸为主料,以羧甲基纤维素、微晶纤维素、硬脂酸镁以及麦芽糖醇为辅料制备而成具有携带方便、服用方便、效果好的特点,同时该产品不含任何色素,无蔗糖,安全无任何毒副作用。
Description
技术领域:
本发明涉及医药保健品技术领域,具体地说是一种茶叶精华解酒片及其制备方法。
背景技术:
众所周知,酒中的主要成分是乙醇,人饮酒后,乙醇除少量在进入人体后,马上随肺部呼吸或经汗腺排出体外,绝大部分进入肝脏,在肝脏中通过乙醇脱氢酶和乙醛脱氢酶的作用下代谢,,生理条件下乙醇经乙醇脱氢酶(ADH)代谢为乙醛;乙醛经乙醛脱氢酶(ALDH)代谢为乙酸,其中乙醛经过乙醛脱氢酶转化为乙酸的速度决定了酒精对人体肝脏的伤害程度,如果乙醛不能迅速转化为乙酸,则对肝脏的损伤非常严重。此外,体内抗氧化物的多寡也直接影响清除自由基的能力,而自由基已被证实与自由基与肝脏疾病有直接影响。换句话说,人体内乙醛脱氢酶活性的高低,以及抗氧化物的多寡决定了酒精对人体肝脏的损害程度。
在公开号CN101797279B的中国专利文献中公开了“一种具有解酒作用的保健品”,它由L-阿拉伯糖和葛根全粉组成,通过粉碎、混合、筛分制成胶囊剂或片剂,此类产品配有中草药成分葛根,可溶性差,口感粗糙,广大消费者很难接受。
而目前市场上销售的解酒类产品主要以姜黄、葛根、牡蛎等中药制剂为主成分,如公开号CN101919802A的中国专利公开了一种“口腔吸收固体解酒泡腾制剂”,它的药效组分由天然咖啡因以及山楂提取物、绿茶提取物、枳子提取物、肉豆蔻提取物、茯苓提取物、草果提取物、葛根提取物、酸枣仁提取物、桂枝提取物、高良姜提取物、菊花提取物的一种或者几种组成,同时辅以碱性组分、酸性组分、包裹材料和辅料,制成解酒泡腾制剂,其解酒的机理是利用中药成分分解酒精,但二次分解起效慢,往往达不到效果,且在解酒的同时会对肝肾造成代谢负担,不建议长期服用。
申请号CN201410169768.1的发明专利记述了普洱茶提取物可明显提高胃和肝中ADH、ALDH活性,降低全血乙醇浓度和乙醛浓度,减少乙醇的吸收;
申请号CN201410169615.7的发明专利记述了一种普洱茶提取物茶褐素具有解酒功效,通过小鼠实验证明,其具有可明显提高胃和肝中ADH、ALDH活性,降低全血乙醇浓度和乙醛浓度,降低血清中AST/ALT,说明茶褐素具有预防醉酒和解酒的作用。
此两篇专利均记述了普洱茶提取物,特别是茶褐素具有的激活ADH、ALDH活性的作用,但普洱茶作为红茶,在制作过程中流失了绿茶中绝大多数的对人体有益的茶多酚,且维生素的流失也较为严重。
所以用普洱茶为代表的红茶为原料制备解酒保健品或药物具有一定的局限性。
所以如何从绿茶中提取有用的具有解酒功效的精华素,并且将此精华素制成可以口服的制剂成为一个重要的课题。
申请号201410347125.1的发明记述了茶叶精华粉的制备方法,采用特定发酵的办法将大分子化合物分解为甘露聚醇,而其他小分子化合物茶多酚和维生素不受影响。发酵产生的液体通过过滤、浓缩制得茶叶精华粉,其制备方法不同于CN201410169768.1所述的普洱茶提取物的制备方法,其营养成分完全不足,特别是其中含有对人体具有重要功能作用的多种营养素,其中含有的SOD-l抗氧化物可清除摄入酒精时造成的自由基以及危害。
L-半胱氨酸、主要用于医药、化妆品、生化研究等方面。用于面包料中,以促进谷朊形成及促进发酵、出模、防止老化等。用于天然果汁中,以防止维生素C氧化和防止果汁变成褐色。该品有解毒作用,是一种氨基酸类解毒药,它参与细胞的还原过程和肝脏内的磷脂代谢,有保护肝细胞不受损害,促进肝脏功能恢复和旺盛的药理效应。现今已在医药、食品添加剂和化妆品中广泛应用。L-半胱氨酸是以微生物转化法制生产,性状为白色结晶或晶体粉末,易溶于水,无臭,无毒,人体食用后安全无负担。经过前期研究发现,L-半胱氨酸对乙醛具有较强的“亲和力”生成亚胺类(2-甲基四氢噻唑-4-羧酸)较为稳定的物质,直接排除体外,从而降低乙醛的毒性,因此L-半胱氨酸也能有效地解除乙醇的毒性。L-半胱氨酸可以与自由基发生反应,进而清除乙醇氧化过程中产生的自由基,降低脂质过氧化等反应速率。另外,L-半胱氨酸还可转化为胱氨酸,参与受损组织的修复。
而玉米肽中含有非常多的丙氨酸和亮氨酸,并且,玉米肽中的丙氨酸和亮氨酸基本上是以短肽的形式存在的,不需要消化就可以吸收,可加速进入血液循环,参与辅酶I的合成,从而增加了乙醇脱氢酶和乙醛脱氢酶的活性,达到解酒的功效。
发明内容
本发明的技术任务是提供一种茶叶精华解酒片及其制备方法。
本发明的技术任务是按以下方式实现的,该茶叶精华解酒片是以茶叶精华粉、玉米肽、以及L-半胱氨酸为主料,以羧甲基纤维素、微晶纤维素、硬脂酸镁以及麦芽糖醇为辅料制备而成;
所述的主料和辅料的配方重量份配比如下:
茶叶精华粉10—60份、玉米肽5-15份、L-半胱氨酸0.01—0.03份、羧甲基纤维素2-8份、微晶纤维素1-5份、硬脂酸镁0.3-3份、麦芽糖醇5—50份。
该茶叶精华解酒片的制备方法步骤如下:
该茶叶精华解酒片的制备方法步骤如下:
a)粉碎:将茶叶精华粉、玉米肽、羧甲基纤维素,经粉碎机粉碎至200目细粉备用;
b)混合:取L-半胱氨酸、微晶纤维素、硬脂酸镁,与步骤a中的备用混合细粉一起倒入双锥混合机中,混合40-50分钟,使其均匀;
c)压片:将步骤b获得的混合细粉置入压片机中进行压片,制得片剂;
d)包衣:取包衣剂麦芽糖醇,用纯净水充分溶解,制得包衣液,然后利用包衣机对步骤c的片剂进行薄膜包衣,制得茶叶精华解酒片成品。
上述使用的原料的重量份配比如下:
而作为一种优选的制备方法,步骤a中经粉碎机粉碎后粉料粒径为200目。
作为另一种优选的制备方法,所述的步骤c中控制压片机压力为0.6-0.9MPa,片重0.6-1.2g。
而作为茶叶精华粉的制备方法参照申请号CN201410347125.1专利公开的方法进行制备,具体如下:
将可使茶叶发酵的一酵母菌种与茶叶加入一密封容器中;控制该密封容器中的环境温度在该酵母菌种进行醣化作用的最适温度范围中,以使得该酵母菌对茶叶开始进行发酵;当该密封容器中产生甘露聚醣时,将容器内的物质转移至一逆渗透过滤系统中来进行过滤;过滤后所得到的淡黄色液体进行脱水来产生干燥的茶叶精华粉末。
本发明的有益效果:
本发明制得的茶叶精华解酒片具有携带方便、服用方便、效果好的特点,同时该产品不含任何色素,无蔗糖,安全无任何毒副作用。
具体实施方式
实施例1:
1)取茶叶精华粉60g、玉米肽15g,羧甲基纤维素钠2g,经粉碎机粉碎后,过200目的分样筛,得到混合细粉;
2)取L-半胱氨酸0.03g、甘氨酸5g、、微晶纤维素lg、硬脂酸镁3g,混合均匀,与上述混合细粉一起倒入双锥混合机中,混合40分钟,使其均匀;
3)将混合的细粉置入压片机中,控制压片压力为0.6MPa,对混合细粉进行压片,每片约1.1g;
4)取麦芽糖醇5g,加2ml纯净水充分溶解,制备包衣液,然后利用高效智能无孔包衣机对片剂进行薄膜包衣。
5)经过由真空干燥机將包衣后片剂,制得茶叶精华解酒片成品,每片片重约1.2g。
实施例2:
1)取茶叶精华粉10g、玉米肽5g,羧甲基纤维素钠8g,经粉碎机粉碎后,过200目的分样筛,得到混合细粉;
2)取L-半胱氨酸0.01g、甘氨酸5g、、微晶纤维素5g、硬脂酸镁0.3g,混合均匀,与上述混合细粉一起倒入双锥混合机中,混合50分钟,使其均匀;
3)将混合的细粉置入压片机中,控制压片压力为0.9MPa,对混合细粉进行压片,每片约0.5g;
4)取麦芽糖醇50g,加50ml纯净水充分溶解,制备包衣液,然后利用高效智能无孔包衣机对片剂进行薄膜包衣;
5)经过由真空干燥机將包衣后片剂,制得茶叶精华解酒片成品,每片片重约0.6g。
实施例3:
1)取茶叶精华粉40g、玉米肽10g,羧甲基纤维素钠6g,经粉碎机粉碎后,过200目的分样筛,得到混合细粉;
2)取L-半胱氨酸0.02g、微晶纤维素3g、硬脂酸镁0.5g,混合均匀,与上述混合细粉一起倒入双锥混合机中,混合50分钟,使其均匀;
3)将混合的细粉置入压片机中,控制压片压力为0.7MPa,对混合细粉进行压片,每片约0.7g;
4)取麦芽糖醇30g,加50ml纯净水充分溶解,制备包衣液,然后利用高效智能无孔包衣机对片剂进行薄膜包衣;
5)经过由真空干燥机將包衣后片剂,制得茶叶精华解酒片成品,每片片重约0.9g。对比实施例:
取0.4g茶叶精华粉、0.01g玉米肽、0.2mg的L-半胱氨酸放入单粒2号胶囊,做20粒胶囊。
参照国标GB/T5009.171-2003测定茶叶精华粉中超氧化歧化酶SOD的含量,在此基础上测定制成的茶叶精华解酒片的溶出度数据,按照中国药典溶出测定法第二法进行溶出度的测定,溶出介质为0.1mol的盐酸,搅拌速度为75转/min,测定标识物为超氧化歧化酶SOD,结果如下:
实施例 | 实施例1 | 实施例2 | 实施例3 | 对比实施例 |
超氧化歧化酶溶出度(%) | 92 | 94 | 97 | 79 |
可见,本发明制得的茶叶精华解酒片具有很好的溶出性质,活性成分可以更好的溶出,从而可以更好的发挥效果。
通过上面具体实施方式,所述技术领域的技术人员可容易的实现本发明。但是应当理解,本发明并不限于上述的实施方式。在公开的实施方式的基础上,所述技术领域的技术人员可任意组合不同的技术特征,从而实现不同的技术方案。
Claims (5)
1.一种茶叶精华解酒组合物,其特征在于,所述茶叶精华解酒组合物包括茶叶精华粉、玉米肽、L-半胱氨酸、羧甲基纤维素、微晶纤维素、硬脂酸镁以及麦芽糖醇。
2.根据权利要求1所述的一种茶叶精华解酒组合物,其特征在于,所述的配方按重量份如下:茶叶精华粉10-60份、玉米肽5-15份、L-半胱氨酸0.01-0.03份、羧甲基纤维素2-8份、微晶纤维素1-5份、硬脂酸镁0.3-3份、麦芽糖醇5-50份。
3.根据权利要求1-2所述的任一种茶叶精华解酒组合物的制备方法,其特征在于:
该茶叶精华解酒片的制备方法步骤如下:
a)粉碎:将茶叶精华粉、玉米肽、羧甲基纤维素,经粉碎机粉碎至200目细粉备用;
b)混合:取L-半胱氨酸、微晶纤维素、硬脂酸镁,与步骤a中的备用混合细粉一起倒入双锥混合机中,混合40-50分钟,使其均匀;
c)压片:将步骤b获得的混合细粉置入压片机中进行压片,制得片剂;
d)包衣:取包衣剂麦芽糖醇,用纯净水充分溶解,制得包衣液,然后利用包衣机对步骤c的片剂进行薄膜包衣,制得茶叶精华解酒片成品。
4.根据权利要求3所述的一种茶叶精华解酒片的制备方法,其特征在于,所述的步骤a中经粉碎机粉碎后粉料粒径为200目。
5.根据权利要求4所述的一种茶叶精华解酒片的制备方法,其特征在于,所述的步骤c中控制压片机压力为0.6-0.9MPa,片重0.6-1.2g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810800886.6A CN108653716A (zh) | 2018-07-20 | 2018-07-20 | 一种茶叶精华解酒片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810800886.6A CN108653716A (zh) | 2018-07-20 | 2018-07-20 | 一种茶叶精华解酒片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108653716A true CN108653716A (zh) | 2018-10-16 |
Family
ID=63789237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810800886.6A Pending CN108653716A (zh) | 2018-07-20 | 2018-07-20 | 一种茶叶精华解酒片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108653716A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111264655A (zh) * | 2020-03-23 | 2020-06-12 | 生合生物科技(扬州)有限公司 | 一种乳酸菌解酒发酵茶汁及其制作方法 |
CN112715703A (zh) * | 2020-12-30 | 2021-04-30 | 重庆食品工业研究所 | 一种富硒茶含片及其制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1360893A (zh) * | 2000-12-28 | 2002-07-31 | 李孝常 | 一种解毒(酒)护肝复方制剂 |
CN101306074A (zh) * | 2008-04-01 | 2008-11-19 | 中国人民解放军空军航空医学研究所 | 一种解酒护肝的药物组合物 |
CN102028093A (zh) * | 2009-09-29 | 2011-04-27 | 齐齐哈尔大学 | 玉米醒酒肽的制备方法 |
RU2449600C1 (ru) * | 2011-04-26 | 2012-05-10 | Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко" | Биологически активная пищевая добавка |
CN102727474A (zh) * | 2012-06-29 | 2012-10-17 | 天津科技大学 | L-半胱氨酸在制备解酒药物、保护肝脏及肾脏药物中的应用 |
CN103203008A (zh) * | 2013-04-16 | 2013-07-17 | 广州斯威森科技有限公司 | 用于解酒的药物组合物及其制备方法 |
CN105010937A (zh) * | 2015-08-11 | 2015-11-04 | 山东福田药业有限公司 | 一种l-阿拉伯糖解酒片及其制备方法 |
CN105012534A (zh) * | 2014-04-25 | 2015-11-04 | 云南天士力帝泊洱生物茶集团有限公司 | 一种普洱茶提取物在制备预防醉酒药物中的应用 |
CN105265656A (zh) * | 2014-07-22 | 2016-01-27 | 虎鲨国际贸易有限公司 | 茶叶精华的萃取方法 |
CN106262942A (zh) * | 2016-08-22 | 2017-01-04 | 山东福田药业有限公司 | 一种解酒片及其制备方法 |
CN106359702A (zh) * | 2016-08-26 | 2017-02-01 | 青岛汇棠健康科技有限公司 | 一种解酒保健固体茶及其制备方法 |
-
2018
- 2018-07-20 CN CN201810800886.6A patent/CN108653716A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1360893A (zh) * | 2000-12-28 | 2002-07-31 | 李孝常 | 一种解毒(酒)护肝复方制剂 |
CN101306074A (zh) * | 2008-04-01 | 2008-11-19 | 中国人民解放军空军航空医学研究所 | 一种解酒护肝的药物组合物 |
CN102028093A (zh) * | 2009-09-29 | 2011-04-27 | 齐齐哈尔大学 | 玉米醒酒肽的制备方法 |
RU2449600C1 (ru) * | 2011-04-26 | 2012-05-10 | Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко" | Биологически активная пищевая добавка |
CN102727474A (zh) * | 2012-06-29 | 2012-10-17 | 天津科技大学 | L-半胱氨酸在制备解酒药物、保护肝脏及肾脏药物中的应用 |
CN103203008A (zh) * | 2013-04-16 | 2013-07-17 | 广州斯威森科技有限公司 | 用于解酒的药物组合物及其制备方法 |
CN105012534A (zh) * | 2014-04-25 | 2015-11-04 | 云南天士力帝泊洱生物茶集团有限公司 | 一种普洱茶提取物在制备预防醉酒药物中的应用 |
CN105265656A (zh) * | 2014-07-22 | 2016-01-27 | 虎鲨国际贸易有限公司 | 茶叶精华的萃取方法 |
CN105010937A (zh) * | 2015-08-11 | 2015-11-04 | 山东福田药业有限公司 | 一种l-阿拉伯糖解酒片及其制备方法 |
CN106262942A (zh) * | 2016-08-22 | 2017-01-04 | 山东福田药业有限公司 | 一种解酒片及其制备方法 |
CN106359702A (zh) * | 2016-08-26 | 2017-02-01 | 青岛汇棠健康科技有限公司 | 一种解酒保健固体茶及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨希: "普洱茶珍抗醉解酒作用实验研究", 《万方数据知识服务平台-学位论文》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111264655A (zh) * | 2020-03-23 | 2020-06-12 | 生合生物科技(扬州)有限公司 | 一种乳酸菌解酒发酵茶汁及其制作方法 |
CN112715703A (zh) * | 2020-12-30 | 2021-04-30 | 重庆食品工业研究所 | 一种富硒茶含片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3151843B1 (en) | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof | |
JP6064156B2 (ja) | 深部体温上昇剤 | |
CN106975069B (zh) | 一种保肝护肝组合物及其制备方法 | |
CN101524377A (zh) | 破壁灵芝孢子粉与环糊精的组合物及其制备方法 | |
US20190314298A1 (en) | Compositions for preventing and relieving hangover & liver damage which occur due to alcohol consumption | |
CN104306617A (zh) | 含有玛咖和阿萨伊果的组合物及其制备方法和应用 | |
JP6355248B2 (ja) | 交感神経活発化剤 | |
CN104784370A (zh) | 一种能够清除自由基的抗氧化药物组合物及其制备方法 | |
CN105010937A (zh) | 一种l-阿拉伯糖解酒片及其制备方法 | |
CN103933106A (zh) | 具有降压作用的蓝莓果渣提取物的制备方法及冲剂 | |
CN1762474A (zh) | 午时茶泡腾片 | |
CN108653716A (zh) | 一种茶叶精华解酒片及其制备方法 | |
CN106174484A (zh) | 具有止咳平喘功效的酵素组合物、泡腾颗粒及制法 | |
CN103566282B (zh) | 一种抗肿瘤作用中药组合物及制备方法 | |
CN112618608A (zh) | 具有解酒功能的组合物及其制备方法和应用 | |
JP6108352B2 (ja) | 疲労改善組成物 | |
CN102100902A (zh) | 四逆泡腾片 | |
CN102302117B (zh) | 罗汉果维生素c泡腾片及其制备工艺 | |
CN109198352A (zh) | 一种蜂胶固体饮料粉及其制备方法 | |
CN102462740B (zh) | 一种解酒保肝的药物组合物及其制备方法 | |
CN101491605A (zh) | 一种具有降血糖功能的组合物及其制备方法 | |
CN101190251B (zh) | 红景天咀嚼片及其制备方法和用途 | |
KR102402571B1 (ko) | 홍삼 츄어블정의 제조 방법 | |
JP2002306092A (ja) | 抗酸化活性プロポリス製品 | |
US20190320688A1 (en) | Compositions for preventing and relieving hangover & liver damage which occur due to alcohol consumption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181016 |